Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
crispr
4
×
life sciences
national blog main
biotech
boston
boston top stories
deals
national top stories
san francisco blog main
abbvie
allergan
clinical trials
editas medicine
fda
gene editing
gilead sciences
san francisco top stories
sickle cell disease
startups
akouos
alnylam pharmaceuticals
alzheimer's disease
amag pharmaceuticals
amunix
anirvan ghosh
astrazeneca
biogen
bluerock therapeutics
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cerovene
covid-19
cynthia collins
cystic fibrosis
cystic fibrosis foundation
david walt
deerfield management
What
medicines
4
×
bio
editing
gene
years
abbvie
acquisitions
alliance
announced
biotech
ceo
cf
collabs
covid
create
crisis
crispr
cystic
daniel
deal
developer
diagnostic
diseases
editas
exits
experimental
fibrosis
fix
force
genetic
gilead
gilead’s
heats
help
helped
high
human
introduce
ipo
jeff
Language
unset
unknown
Current search:
crispr
×
medicines
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
